Abstract
Sorafenib is a chemotherapy used as first line treatment in primary liver cancers. It is an oral antiangiogenic treatment which reduces the progression of the tumor. Some mild or severe side effects have been reported among which some uncommon cardiac events: myocardial infarction and cardiogenic stroke. Sorafenib treatment remains expensive and not frequently used in Sub-Saharan countries. Thus, few studies have described its side effects in this milieu. We report a case of acute coronary syndrome occurring in a 75-year-old female patient, without cardiovascular risks factors, after nine months of sorafenib chemotherapy at a reduced dose for an unresectable hepatocellular carcinoma in a Sub-Saharan Africa country. The management was conducted by cardiologists, in collaboration with gastroenterologists and oncologists. We decided to completely stop sorafenib chemotherapy. We observed a reduction of the pain 48 hours after her admission, and a regression of electrocardiographic signs after 8 days. In conclusion, the sorafenib treatment can be associated with cardiac events despite the dose reduction.
Highlights
Sorafenib is a chemotherapy drug used in case of some liver, thyroid and kidney cancers
Sorafenib is a chemotherapy used as first line treatment in primary liver cancers
We report a case of acute coronary syndrome occurring in a 75-year-old female patient, without cardiovascular risks factors, after nine months of sorafenib chemotherapy at a reduced dose for an unresectable hepatocellular carcinoma in a Sub-Saharan Africa country
Summary
Sorafenib is a chemotherapy drug used in case of some liver, thyroid and kidney cancers It is an oral Vascular Endothelial Growth Factor Receptor (VEGFR) tyrosine kinase inhibitor. Cardiovascular events are possible, but not frequent They include arterial hypertension, congestive heart failure, cardiomyopathy, acute myocardial infarction, and cardiogenic stroke [5] [6] [7] [8] [9]. We report the case of an acute coronary syndrome in a 75-year-old female patient with low cardiovascular risks, treated with a reduced dose of sorafenib for an unresectable hepatocellular carcinoma complicating a hepatitis C induced compensated liver cirrhosis
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have